Nav: Home

Researchers urge caution in prescribing commonly used drug to treat ADHD

November 24, 2015

Authors of new Cochrane Review remain uncertain about effect of widely used medicine on ADHD symptoms, despite large amount of research. Some evidence of increased sleeplessness and loss of appetite leads researchers to encourage more caution in use of methylphenidate.

The Cochrane Library publishes one of the most comprehensive assessments to date on the benefits and harms of a widely prescribed drug used to treat Attention Deficit Hyperactivity Disorder (ADHD).

ADHD is one of the most commonly diagnosed childhood disorders and can continue through adolescence into adulthood. Symptoms include difficulty focusing attention and remaining "on task", excessively impulsive behaviour, and extreme hyperactivity. It is estimated to affect about 5% of children, and diagnosis is based on clinical judgement rather than objective diagnostic markers.

Methylphenidate, more commonly known by its brand names - Ritalin®, Concerta®, Medikinet®, and Equasym®, amongst others - has been used to treat ADHD for more than 50 years. A team of Cochrane researchers has carefully evaluated and summarized the findings from all of the available randomized trials of this widely used drug.

This new Cochrane Review includes data from 185 randomized controlled trials involving more than 12,000 children or adolescents. The studies were conducted mainly in the US, Canada, and Europe, included males and females from ages 3-18, and all compared methylphenidate with either a dummy pill or no intervention.

When researchers combined data from identified trials, they found that methylphenidate led to modest improvements in ADHD symptoms, general behaviour, and quality of life. Analysis of adverse effects showed that children were more likely to experience sleep problems and loss of appetite while taking methylphenidate. However, the researchers' confidence in all results was very low: it was apparent from assessing the included trials that it would have been possible for people involved in the trials to have been aware of which treatment the children were taking. In addition, the reporting of results was not complete in many of the trials, and for some analyses there was variation among trial results.

Based upon this information, the researchers urge clinicians to be cautious in prescribing methylphenidate, and to weigh up the benefits and risks more carefully.

The team of 18 researchers was led by Professor Ole Jakob Storebø, Clinical Psychologist from the Psychiatric Research Unit in Region Zealand, Denmark. He says, "This review highlights the need for long-term, large, better-quality randomized trials so that we can determine the average effect of this drug more reliably."

Co-author Camilla Groth MD added, "This review shows very limited quality evidence for the effects of methylphenidate on children and adolescents with ADHD. Some might benefit, but we still don't know which patients will do so. Clinicians prescribing methylphenidate must take account of the poor quality of the evidence, monitor treatment carefully, and weigh up the benefits and adverse effects."

Another co-author, Dr Morris Zwi, Consultant Child & Adolescent Psychiatrist added, "This evidence is important for health professionals and parents of children with ADHD. Our expectations of this treatment are probably greater than they should be, and whilst our review shows some evidence of benefit, we should bear in mind that this finding was based on very low-quality evidence. What we still need are large, well-conducted trials in order to clarify the risks versus the benefits for this widely used treatment."

The researchers have also urged that clinicians and families should not rush to discontinue using methylphenidate. Dr Zwi added, "If a child or young person has experienced benefits without experiencing adverse effects, then there may be good clinical grounds to continue using it. Patients and their parents should discuss any decision to stop treatment with their health professional before doing so."

An abridged version of the Cochrane Review will appear in the BMJ later this week.
-end-
Full citation:"Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD)." Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. CRG: Developmental, Psychosocial and Learning Problems Group. Cochrane Database of Systematic Reviews 2015, Intervention review. DOI: 10.1002/14651858.CD009885.pub2

URL Upon publication: http://doi.wiley.com/10.1002/14651858.CD009885.pub2

For further information please contact: Jo Anthony, Senior Media and Communications Officer, Cochrane at M +44(0) 7582 726 634 or janthony@cochrane.org, pressoffice@cochrane.org.

Authors: Ole Jakob Storebø, Clinical Psychologist, PhD, Child and Adolescent Psychiatric Department; Senior Researcher, Psychiatric Research Unit Roskilde, Region Zealand; Honorary Associate Professor, University of Southern Denmark; Editor-in-Chief: Journal of Child and Adolescent Psychiatry and Psychology in Denmark and Dr Morris Zwi MBBCh, FRCPsych, Consultant Child & Adolescent Psychiatrist, CAMHS Clinical Lead in Islington, London.

About Cochrane

Cochrane is a global independent network of researchers, professionals, patients, carers and people interested in health. Cochrane produces reviews which study all of the best available evidence generated through research and make it easier to inform decisions about health. These are called systematic reviews. Cochrane is a not-for profit organisation with collaborators from more than 120 countries working together to produce credible, accessible health information that is free from commercial sponsorship and other conflicts of interest. Our work is recognised as representing an international gold standard for high quality, trusted information.

Find out more at http://cochrane.org

Follow us on twitter @cochranecollab

About Wiley

Wiley is a global provider of knowledge and knowledge-enabled services that improve outcomes in areas of research, professional practice and education. Through the Research segment, the Company provides digital and print scientific, technical, medical, and scholarly journals, reference works, books, database services, and advertising. The Professional Development segment provides digital and print books, online assessment and training services, and test prep and certification. In Education, Wiley provides education solutions including online program management services for higher education institutions and course management tools for instructors and students, as well as print and digital content. The Company's website can be accessed at http://www.wiley.com.

If you would like to request complimentary media access to the contents of The Cochrane Library, please email sciencenewsroom@wiley.com.

Wiley

Related Adhd Articles:

Autism and ADHD share genes
Researchers from the national psychiatric project iPSYCH have found that autism and ADHD share changes in the same genes.
ADHD across racial/ethnic groups
This study of patients from diverse racial/ethnic backgrounds who received care at the Kaiser Permanente Northern California health system looked at how common attention-deficit/hyperactivity disorder (ADHD) diagnoses were over a 10-year period across seven racial/ethnic groups.
Cycles of reward: New insight into ADHD treatment
Researchers at the Okinawa Institute of Science and Technology Graduate University (OIST) in collaboration with scientists at the University of Otago and the University of Auckland in New Zealand, investigated the actions of the drug in rats.
Young mums more likely to have kids with ADHD
Young mothers have a greater chance of having a child with attention deficit hyperactivity disorder (ADHD) according to new research from the University of South Australia.
ADHD medication: How much is too much for a hyperactive child?
When children with ADHD don't respond well to Methylphenidate (MPH, also known as Ritalin) doctors often increase the dose.
Antipsychotic use in youths with ADHD is low, but still cause for concern
A new study eased fears about the proportion of youths with ADHD taking antipsychotic drugs, but still found that many prescriptions may be inappropriate.
How stimulant treatment prevents serious outcomes of ADHD
Analysis quantifies the extent which stimulant treatment reduces serious outcomes in children and young adults with ADHD.
Did Leonardo da Vinci have ADHD?
Leonardo da Vinci produced some of the world's most iconic art, but historical accounts show that he struggled to complete his works.
More sleep may help teens with ADHD focus and organize
Teenagers with attention deficit hyperactivity disorder (ADHD) may benefit from more sleep to help them focus, plan and control their emotions.
Researchers have found the first risk genes for ADHD
A major international collaboration headed by researchers from the Danish iPSYCH project, the Broad Institute of Harvard and MIT, Massachusetts General Hospital, SUNY Upstate Medical University, and the Psychiatric Genomics Consortium has for the first time identified genetic variants which increase the risk of ADHD.
More ADHD News and ADHD Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Making Amends
What makes a true apology? What does it mean to make amends for past mistakes? This hour, TED speakers explore how repairing the wrongs of the past is the first step toward healing for the future. Guests include historian and preservationist Brent Leggs, law professor Martha Minow, librarian Dawn Wacek, and playwright V (formerly Eve Ensler).
Now Playing: Science for the People

#566 Is Your Gut Leaking?
This week we're busting the human gut wide open with Dr. Alessio Fasano from the Center for Celiac Research and Treatment at Massachusetts General Hospital. Join host Anika Hazra for our discussion separating fact from fiction on the controversial topic of leaky gut syndrome. We cover everything from what causes a leaky gut to interpreting the results of a gut microbiome test! Related links: Center for Celiac Research and Treatment website and their YouTube channel
Now Playing: Radiolab

The Flag and the Fury
How do you actually make change in the world? For 126 years, Mississippi has had the Confederate battle flag on their state flag, and they were the last state in the nation where that emblem remained "officially" flying.  A few days ago, that flag came down. A few days before that, it coming down would have seemed impossible. We dive into the story behind this de-flagging: a journey involving a clash of histories, designs, families, and even cheerleading. This show is a collaboration with OSM Audio. Kiese Laymon's memoir Heavy is here. And the Hospitality Flag webpage is here.